ArticleBMC psychiatry2026
Clinical effectiveness of long-acting injectable antipsychotics in schizophrenia spectrum disorders: real-world mirror-image evidence.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correction: Clinical effectiveness of long-acting injectable antipsychotics in schizophrenia spectrum disorders: real-world mirror-image evidence.BMC psychiatry · 2026Article
- Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics.Frontiers in psychiatry · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-acting injectable (LAI) antipsychotics are increasingly utilized to address non-adherence and improve clinical stability in patients with chronic psychiatric disorders. However, real-world data comparing different LAI formulations remain limited. This retrospective mirror-image study evaluated the clinical effectiveness of LAI antipsychotics among 149 individuals who received treatment at a community mental health center. Clinical outcomes, including hospitalizations, duration of hospitalization, psychiatric emergency visits, and relapses, were compared across equal-length pre- and post-treatment periods. Following LAI initiation, significant reductions were observed in hospitalizations, emergency visits, and relapse rates across the full sample (p < .001). Cox regression analyses revealed that LAI treatment was associated with a lower hazard of hospitalizations, emergency visits, and relapses. Comparative analyses among LAI formulations showed that while all agents were effective, paliperidone palmitate 1-month (PP1M) and aripiprazole once-monthly (AOM) were associated with greater improvements in acute service utilization than paliperidone 3-month (PP3M). Furthermore, AOM was linked to significantly lower concurrent oral antipsychotic use despite similar total antipsychotic doses. These findings suggest that LAI antipsychotics offer substantial benefits in reducing healthcare utilization and enhancing clinical outcomes in real-world psychiatric care. PP1M and AOM may offer superior effectiveness in certain clinical domains, although prospective controlled studies are warranted to confirm formulation-specific advantages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.